Innovassynth Technologies (India) Ltd
Incorporated in 2008, Innovassynth Investments Ltd is a holding and investment company
- Market Cap ₹ 544 Cr.
- Current Price ₹ 72.1
- High / Low ₹ 140 / 50.1
- Stock P/E
- Book Value ₹ 10.8
- Dividend Yield 0.00 %
- ROCE -9.18 %
- ROE -11.1 %
- Face Value ₹ 10.0
Pros
- Promoter holding has increased by 42.2% over last quarter.
Cons
- Stock is trading at 6.66 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -6.02% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Financial Services Financial Services Finance Investment Company
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.28 | 0.37 | 1.30 | 0.50 | 3.96 | 11.72 | |
| Operating Profit | -0.28 | -0.37 | -1.30 | -0.50 | -3.96 | -11.72 |
| OPM % | ||||||
| 0.00 | 1.86 | 0.02 | 0.00 | -0.33 | 7.40 | |
| Interest | 0.24 | 0.27 | 0.30 | 0.34 | 0.40 | 0.45 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.52 | 1.22 | -1.58 | -0.84 | -4.69 | -4.77 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -0.52 | 1.22 | -1.58 | -0.84 | -4.69 | -4.77 | |
| EPS in Rs | -0.21 | 0.50 | -0.65 | -0.35 | -1.68 | -1.71 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 27% |
| 5 Years: | 65% |
| 3 Years: | 55% |
| 1 Year: | -10% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| Last Year: | -11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 24.28 | 24.28 | 24.28 | 27.98 | 27.98 |
| Reserves | 12.68 | 12.64 | 11.79 | 14.26 | 2.32 |
| 2.85 | 3.24 | 3.59 | 4.40 | 4.86 | |
| 0.94 | 1.22 | 1.56 | 1.96 | 2.20 | |
| Total Liabilities | 40.75 | 41.38 | 41.22 | 48.60 | 37.36 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 40.74 | 41.35 | 41.21 | 48.53 | 37.28 |
| 0.01 | 0.03 | 0.01 | 0.07 | 0.08 | |
| Total Assets | 40.75 | 41.38 | 41.22 | 48.60 | 37.36 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -0.32 | -0.34 | -0.33 | -0.73 | ||
| 0.00 | 0.00 | 0.00 | 0.00 | ||
| 0.32 | 0.36 | 0.32 | 0.77 | ||
| Net Cash Flow | 0.00 | 0.02 | -0.01 | 0.04 | |
| Free Cash Flow | -0.32 | -0.34 | -0.33 | -0.73 | |
| CFO/OP | 86% | 26% | 66% | 18% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | |||||
| Inventory Days | |||||
| Days Payable | |||||
| Cash Conversion Cycle | |||||
| Working Capital Days | |||||
| ROCE % | -3.20% | -1.25% | -9.18% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Turnover (Revenue) Rs. Crore ・Standalone data |
|
||||||
| Capital Structure (Gearing Ratio) times ・Standalone data |
|||||||
| Customer Concentration (Top Customer Revenue Share) % ・Standalone data |
|||||||
Documents
Announcements
- Closure of Trading Window 31 Mar
-
Announcement under Regulation 30 (LODR)-Raising of Funds
27 Mar - Board approved rights issue up to ₹70,00,00,000 and formed Rights Issue Committee.
-
Announcement under Regulation 30 (LODR)-Issue of Securities
27 Mar - Board proposes rights issue up to ₹70 crore; Rights Issue Committee constituted.
-
Board Meeting Outcome for Board Meeting Outcome For The Meeting Held On 27Th March, 2026 For The Approval Of Raising Funds By Way Of Issue Of Equity Shares Of The Company On Right Issue Basis.
27 Mar - Board approved rights issue up to ₹70 crore; Rights Issue Committee constituted (27-Mar-2026).
-
Board Meeting Intimation for Fund Raising.
24 Mar - Board meeting March 27, 2026 to consider issuing equity/other securities (rights/preferential/QIP).
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
Business Associate:[1][2][3]
Company invested in Innovassynth Technologies (India) Limited (~31.79%), which is its Associate from 12 February 2022. ITIL is R&D and technology-based Organization engaged in developing, scaling up and manufacturing of specialty chemicals and pharmaceutical Intermediates. Key focus business areas are customs synthesis, contract research & manufacturing of specialty chemicals, toll manufacture of chemicals and similar businesses. It also supplies protected nucleosides and modified phosphonamidites used for clinical, diagnostic and therapeutic oligonucleotides applications. On 12th February 2022, Managing Director of Innovassynth Technologies Ltd was appointed as Managing Director of company resulting into establishment of significant influence over ITIL. Company has not diversified its investment in other entities except ITIL